Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Aspire Biopharma and OnKure Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| OnKure Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Volatility & Risk
Aspire Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Profitability
This table compares Aspire Biopharma and OnKure Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | N/A | N/A | -398.04% |
| OnKure Therapeutics | N/A | -61.02% | -55.99% |
Earnings & Valuation
This table compares Aspire Biopharma and OnKure Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 644.80 | -$24.48 million | ($116.67) | -0.04 |
| OnKure Therapeutics | N/A | N/A | -$59.52 million | ($4.33) | -0.97 |
Aspire Biopharma has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
OnKure Therapeutics beats Aspire Biopharma on 8 of the 12 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
